source
- Roche says its late-stage pipeline is full, sees growth through 2030Roche's CEO Thomas Schinecker told analysts that the company has 19 investigational medicines that could launch by 2030, indicating a robust late-stage pipeline. He added that the depth of the pip…
- Biopharma firms must prioritize hiring and retaining commercial talent for successful drug launchesA BioSpace webinar brought together commercial leaders and a recruiting specialist to discuss how biopharma companies can better hire and keep commercial staff as they prepare for new product launc…